$2.3 Billion is the total value of Redmile Group, LLC's 70 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 45.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Sell | AMICUS THERAPEUTICS INC | $144,271,000 | -13.1% | 10,025,770 | -9.0% | 6.27% | -23.4% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $77,540,000 | +57.2% | 2,209,107 | -2.6% | 3.37% | +38.6% |
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $70,150,000 | -7.8% | 2,021,600 | -10.0% | 3.05% | -18.8% |
| SGEN | Sell | SEATTLE GENETICS INC | $61,847,000 | -38.3% | 1,156,021 | -37.3% | 2.69% | -45.7% |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $50,969,000 | +6.6% | 2,815,988 | -2.6% | 2.22% | -6.1% |
| LIVN | Sell | LIVANOVA PLC | $49,198,000 | +11.0% | 615,588 | -2.7% | 2.14% | -2.2% |
| RGNX | Sell | REGENXBIO INC | $47,390,000 | -13.8% | 1,425,272 | -14.5% | 2.06% | -24.0% |
| ELGX | Sell | ENDOLOGIX INC | $31,715,000 | +8.7% | 5,928,101 | -9.4% | 1.38% | -4.2% |
| ICUI | Sell | ICU MED INC | $30,234,000 | -19.4% | 139,972 | -30.6% | 1.31% | -29.0% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $29,041,000 | -19.6% | 929,326 | -27.9% | 1.26% | -29.1% |
| PRAH | Sell | PRA HEALTH SCIENCES INC | $22,823,000 | -25.5% | 250,614 | -37.7% | 0.99% | -34.3% |
| CMRX | Sell | CHIMERIX INC | $17,746,000 | -20.0% | 3,832,778 | -9.3% | 0.77% | -29.4% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $14,658,000 | +22.6% | 683,880 | -5.4% | 0.64% | +8.0% |
| SYRS | Sell | SYROS PHARMACEUTICALS INC | $6,200,000 | -34.3% | 637,232 | -0.7% | 0.27% | -42.1% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $5,026,000 | -35.3% | 1,558,392 | -2.8% | 0.22% | -42.8% |
| PETQ | Sell | PETIQ INC | $4,900,000 | -26.7% | 224,343 | -9.1% | 0.21% | -35.5% |
| OVID | Sell | OVID THERAPEUTICS INC | $3,087,000 | -18.1% | 312,782 | -30.7% | 0.13% | -28.0% |
| CASC | Sell | CASCADIAN THERAPEUTICS INC | $2,403,000 | -70.2% | 649,446 | -67.0% | 0.10% | -73.8% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $318,000 | -9.1% | 5,327 | -63.5% | 0.01% | -17.6% |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -1,360 | -100.0% | -0.01% | – |
| LHCG | Exit | LHC GROUP INC | $0 | – | -3,310 | -100.0% | -0.01% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -6,640 | -100.0% | -0.02% | – |
| HOLX | Exit | HOLOGIC INC | $0 | – | -20,000 | -100.0% | -0.04% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -332,310 | -100.0% | -0.10% | – |
| Exit | NEURODERM LTD | $0 | – | -76,729 | -100.0% | -0.15% | – | |
| AMED | Exit | AMEDISYS INC | $0 | – | -283,648 | -100.0% | -0.78% | – |
| MEDP | Exit | MEDPACE HLDGS INC | $0 | – | -499,640 | -100.0% | -0.79% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -603,493 | -100.0% | -0.87% | – |
| DPLO | Exit | DIPLOMAT PHARMACY INC | $0 | – | -957,155 | -100.0% | -0.98% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -723,330 | -100.0% | -1.24% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -189,008 | -100.0% | -1.42% | – |
| MOH | Exit | MOLINA HEALTHCARE INC | $0 | – | -461,074 | -100.0% | -1.56% | – |
| Exit | ARRAY BIOPHARMA INCnote 3.000% 6/0 | $0 | – | -19,000,000 | -100.0% | -1.69% | – | |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -338,536 | -100.0% | -1.70% | – |
| AET | Exit | AETNA INC NEW | $0 | – | -233,837 | -100.0% | -1.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-18 |
| 4 | 2024-06-14 |
| 4 | 2024-06-11 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.